CAPTIVATE: 3-Yr Follow-up Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL

June 3-7, 2022; Chicago, Illinois
The 3-year update of the CAPTIVATE fixed-duration cohort continues to show deep and durable responses with first-line ibrutinib + venetoclax in CLL/SLL including in patients with high-risk features.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seattle Genetics

Related Content

Watch a short video that provides an expert review of the evolution in CLL treatment over the past several years, from Clinical Care Options (CCO)

Nicole Lamanna, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 15, 2022 Expired: August 14, 2023

In slides from Clinical Care Options (CCO), gain expert insights into the evolution in CLL treatment over the past several years

Nicole Lamanna, MD Released: August 15, 2022

Comentario experto de los datos de la EHA 2022 sobre inhibidores de la QBT para LLC y LCM de Clinical Care Options (CCO)

person default Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Expertengespräch über die Daten der EHA 2022 zu BTK-Inhibitoren für CLL und MCL, von Clinical Care Options (CCO)

person default Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings